Immunogen (IMGN) Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. MU
3. FDX
4. SPY
5. META
6. ABBV
7. NVDA
8. BLZE
9. IBM
10. NKE

Go back to Immunogen (IMGN) Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer

Immunogen (IMGN) Prices Upsized 11.64M Share Offering at $6.60/sh

December 2, 2021 5:52 AM EST

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 11,636,364 shares of its common stock at a price of $6.60 per share, before underwriting discounts and commissions, and to certain... More

Immunogen (IMGN) Shares Up 40%, Following Positive SORAYA Trial Results

November 30, 2021 8:10 AM EST

Immunogen (NASDAQ: IMGN) shares are gaining nearly 40% in pre-market on heavy volume, following positive results from the company's SORAYA clinical trial.

... More